RadNet Inc. (RDNT) Receives $14.67 Average PT from Analysts

Share on StockTwits

RadNet Inc. (NASDAQ:RDNT) has been given a consensus recommendation of “Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $14.67.

A number of equities research analysts have recently weighed in on the company. BidaskClub downgraded RadNet from a “hold” rating to a “sell” rating in a report on Thursday, August 30th. Zacks Investment Research downgraded RadNet from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th.

RDNT opened at $13.65 on Wednesday. RadNet has a fifty-two week low of $9.50 and a fifty-two week high of $15.50. The company has a debt-to-equity ratio of 4.49, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $663.92 million, a PE ratio of 47.07, a PEG ratio of 4.91 and a beta of 0.22.

RadNet (NASDAQ:RDNT) last posted its earnings results on Thursday, August 9th. The medical research company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). RadNet had a positive return on equity of 17.00% and a negative net margin of 0.64%. The firm had revenue of $244.40 million for the quarter, compared to analyst estimates of $239.34 million. During the same period in the prior year, the business posted $0.11 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. sell-side analysts predict that RadNet will post 0.35 EPS for the current year.

In related news, insider Jeffrey L. Linden sold 10,000 shares of the firm’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $12.97, for a total value of $129,700.00. Following the transaction, the insider now owns 912,001 shares in the company, valued at $11,828,652.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 40,000 shares of company stock worth $548,100 in the last 90 days. 7.56% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in shares of RadNet in the first quarter valued at approximately $114,000. Mackay Shields LLC acquired a new stake in shares of RadNet in the first quarter valued at approximately $3,250,000. Trexquant Investment LP grew its position in shares of RadNet by 207.8% in the first quarter. Trexquant Investment LP now owns 47,923 shares of the medical research company’s stock valued at $690,000 after purchasing an additional 32,353 shares during the last quarter. American Century Companies Inc. grew its position in shares of RadNet by 167.0% in the first quarter. American Century Companies Inc. now owns 57,155 shares of the medical research company’s stock valued at $823,000 after purchasing an additional 35,751 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its position in shares of RadNet by 161.5% in the first quarter. Campbell & CO Investment Adviser LLC now owns 60,240 shares of the medical research company’s stock valued at $867,000 after purchasing an additional 37,200 shares during the last quarter. Institutional investors own 60.45% of the company’s stock.

About RadNet

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Article: Diversification in Your Portfolio

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply